Connor, Clark & Lunn Investment Management Ltd. Castle Biosciences Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 126,431 shares of CSTL stock, worth $2.91 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
126,431
Previous 176,889
28.53%
Holding current value
$2.91 Million
Previous $3.54 Million
27.11%
% of portfolio
0.01%
Previous 0.02%
Shares
13 transactions
Others Institutions Holding CSTL
# of Institutions
167Shares Held
27.2MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY3.04MShares$70.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$49.9 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.8MShares$41.4 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.49MShares$34.3 Million2.2% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.38MShares$31.7 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $605M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...